IDEAYA BIOSCIENCES INC (IDYA) — insider trading
Health Care · NASDAQ
IDEAYA BIOSCIENCES INC (IDYA) has 17 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase and 3 open-market sales among the most recent 17 (latest 2026-10-06).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | Hata Yujiro S | Director, Officer (President and CEO) | Option exercise / conversion (derivative) | 26,338 | — | $0 | Form 4 |
| 2026-10-06 | Hata Yujiro S | Director, Officer (President and CEO) | Open-market sale | 800 | $38.26 | $30.6K | Form 4 |
| 2026-10-06 | Hata Yujiro S | Director, Officer (President and CEO) | Open-market sale | 25,538 | $37.39 | $954.8K | Form 4 |
| 2026-10-06 | Hata Yujiro S | Director, Officer (President and CEO) | Option exercise / conversion | 26,338 | $4.31 | $113.5K | Form 4 |
| 2026-07-07 | Ruiz Briseno Andres | Officer (Chief Accounting Officer) | Option exercise / conversion (derivative) | 9,550 | — | $0 | Form 4 |
| 2026-07-07 | Ruiz Briseno Andres | Officer (Chief Accounting Officer) | Open-market sale | 9,550 | $40.01 | $382.1K | Form 4 |
| 2026-07-07 | Ruiz Briseno Andres | Officer (Chief Accounting Officer) | Option exercise / conversion | 9,550 | $12.86 | $122.8K | Form 4 |
| 2026-06-16 | Hampton Malcolm Garret | Director | Grant / award / vesting (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-06-16 | MACKEY CATHERINE J | Director | Grant / award / vesting (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-06-16 | Morrison Scott W | Director | Grant / award / vesting (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-06-16 | ROSEN TERRY J | Director | Grant / award / vesting (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-06-16 | Stein Jeffrey | Director | Grant / award / vesting (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-06-16 | YARNO WENDY L | Director | Grant / award / vesting (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-03-02 | Stein Jeffrey | Director | Open-market purchase | 50,000 | $32.96 | $1.65M | Form 4 |
| 2026-01-30 | Beaupre Darrin | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 175,000 | — | $0 | Form 4 |
| 2026-01-30 | WHITE MICHAEL ANTHONY | Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 190,000 | — | $0 | Form 4 |
| 2026-01-30 | Bleharski Joshua | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 170,000 | — | $0 | Form 4 |
Ask the chat about IDYA's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: IDEAYA BIOSCIENCES INC (IDYA).
Last updated 2026-10-06 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.